These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37334852)

  • 1. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
    Matthews AH; Perl AE; Luger SM; Gill SI; Lai C; Porter DL; Skuli S; Bruno XJ; Carroll MP; Freyer CW; Carulli A; Babushok DV; Frey NV; Hexner EO; Martin ME; McCurdy SR; Stadtmauer EA; Loren AW; Paralkar VR; Maillard IP; Pratz KW
    Am J Hematol; 2023 Aug; 98(8):1254-1264. PubMed ID: 37334852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
    Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
    Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y
    Cancer; 2024 Jul; 130(14):2472-2481. PubMed ID: 38470375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
    Acker F; Chromik J; Tiedjen E; Wolf S; Vischedyk JB; Makowka P; Enßle JC; Kouidri K; Sebastian M; Steffen B; Oellerich T; Serve H; Neubauer A; Schäfer JA; Bittenbring JT
    Eur J Haematol; 2024 Nov; 113(5):623-630. PubMed ID: 39023132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.
    Bewersdorf JP; Shimony S; Shallis RM; Liu Y; Berton G; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Bystrom RP; Lindsley RC; Chen EC; Ramos Perez J; Stein A; Pullarkat V; Aldoss I; DeAngelo DJ; Neuberg DS; Stone RM; Garciaz S; Ball B; Stahl M
    Blood Adv; 2024 Sep; 8(18):4845-4855. PubMed ID: 38941537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
    Xin F; Yu YH; Shen XL; Zhang GX
    Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
    Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
    Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
    Sutter T; Schittenhelm M; Volken T; Lehmann T
    Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.
    Hoff FW; Patel PA; Belli AJ; Hansen E; Foss H; Schulte M; Wang CK; Madanat YF
    Leuk Lymphoma; 2023 Jun; 64(6):1123-1128. PubMed ID: 37052347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
    Arora S; Zainaldin C; Bathini S; Gupta U; Worth S; Bachiashvili K; Bhatia R; Godby K; Jamy O; Rangaraju S; Diamond B; Oliver JD; Salzman D; Di Stasi A; Vachhani P
    Leuk Res; 2022 Jun; 117():106844. PubMed ID: 35487134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
    Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
    Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
    Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
    Gershon A; Ma E; Xu T; Montez M; Naqvi K; Ku G; Cheng WW; Flahavan EM; Kota V; Greenwald DR
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e222-e231. PubMed ID: 36925388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
    Liang P; Xie Y; Liu Z; Wang D; Li Q; Lu Y; Xue S; Wang Y; Chen S; Wu D; Fu J
    Br J Haematol; 2024 Apr; 204(4):1219-1226. PubMed ID: 38180132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
    Rausch CR; DiNardo CD; Maiti A; Jammal NJ; Kadia TM; Marx KR; Borthakur G; Savoy JM; Pemmaraju N; DiPippo AJ; Daver NG; Chew SM; Sasaki K; Issa GC; Short NJ; Takahashi K; Ohanian MN; Ning J; Xiao L; Alvarado Y; Kontoyiannis DP; Ravandi F; Kantarjian HM; Konopleva MY
    Cancer; 2021 Jul; 127(14):2489-2499. PubMed ID: 33793970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
    Lachowiez CA; Loghavi S; Kadia TM; Daver N; Borthakur G; Pemmaraju N; Naqvi K; Alvarado Y; Yilmaz M; Short N; Ohanian M; Pierce SR; Patel KP; Qiao W; Ning J; Sasaki K; Takahashi K; Jabbour E; Andreeff M; Ravandi F; Kantarjian HM; Konopleva M; DiNardo CD
    Blood Adv; 2020 Apr; 4(7):1311-1320. PubMed ID: 32251497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
    Shimony S; Garcia JS; Keating J; Chen EC; Luskin MR; Stahl M; Neuberg DS; DeAngelo DJ; Stone RM; Lindsley RC
    Leukemia; 2024 Jul; 38(7):1494-1500. PubMed ID: 38538860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
    Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
    J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia].
    Xu MZ; Qiao M; Sun AN; Wu DP; Xue SL; Zhou HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1631-1636. PubMed ID: 36476881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML.
    Boisclair S; Zhou E; Naing P; Thakur R; Jou E; Goldberg B; Gladstone DE; Allen SL; Kolitz JE; Chitty DW
    Leuk Res; 2024 Aug; 143():107545. PubMed ID: 38963990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.